What it is
Tesamorelin is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH(1-44)) with a trans-3-hexenoic acid moiety conjugated to the N-terminal tyrosine (MW ~5,135.9 Da, molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S, CAS 218949-48-5). The trans-3-hexenoyl modification is the structural innovation that makes the molecule a drug rather than a research peptide: it confers resistance to dipeptidyl aminopeptidase-4 (DPP-IV) cleavage of the N-terminus, which is the dominant degradation pathway for native GHRH, and extends the subcutaneous elimination half-life from minutes (native GHRH) to roughly 26–38 minutes in HIV patients at steady state. Tesamorelin was developed by Theratechnologies (Montreal), received FDA approval as Egrifta in November 2010 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and is marketed in a lyophilized subcutaneous formulation. In March 2025 the FDA approved a supplemental BLA for Egrifta WR — the F8 formulation — which maintains bioequivalence to the original Egrifta SV product while cutting injection volume by more than 50% and allowing weekly rather than daily reconstitution. Patents on the F8 formulation extend to 2033.
In plain English
Tesamorelin is a lab-made version of a natural hormone your body already produces called growth-hormone-releasing hormone (GHRH). Your brain normally releases GHRH to tell your pituitary gland to make growth hormone. The problem with giving the natural version as a drug is that the body breaks it down within minutes — an enzyme called DPP-IV chops it apart almost immediately. Tesamorelin is a slightly modified version that's resistant to that enzyme, so it lasts long enough to actually do its job (roughly 26–38 minutes in the body after injection). That modification — a small chemical group attached to one end — is the engineering insight that turned a useless-as-a-drug molecule into an FDA-approved medicine. The brand names are Egrifta (approved 2010) and Egrifta WR (approved March 2025, same drug in a more convenient format that needs mixing only once a week instead of daily). It was developed by a Canadian company called Theratechnologies.
How it works
- 01
GHRH-R agonism at pituitary somatotrophs
Tesamorelin binds the extracellular domain of the growth-hormone-releasing-hormone receptor (GHRH-R), a class B1 Gαs-coupled GPCR expressed predominantly on somatotrophs of the anterior pituitary. Receptor activation stimulates adenylyl cyclase, elevates intracellular cAMP, activates PKA, phosphorylates CREB, and drives transcription of the GH1 gene and calcium-dependent exocytosis of GH-containing secretory granules. Receptor affinity is comparable to native GHRH and selectivity for GHRH-R over GHS-R1a (ghrelin receptor) is preserved — tesamorelin does not meaningfully raise cortisol, prolactin, or aldosterone in the studied populations (FDA Clinical Pharmacology Review, NDA 022505, 2010).
In plain English
How it activates the pituitary to release growth hormone
Tesamorelin locks onto a specific receptor on cells in the front part of your pituitary gland (a small gland at the base of your brain). Those cells are the ones whose entire job is making growth hormone. When tesamorelin hits that receptor, it triggers a chain reaction inside the cell — like pressing a button — that ends with those cells releasing stored growth hormone into the bloodstream. Critically, tesamorelin only activates this one specific receptor. It does not meaningfully raise stress hormones (cortisol), prolactin, or aldosterone. It's selective — it does one job.
- 02
N-terminal trans-3-hexenoyl protection against DPP-IV
The trans-3-hexenoic acid moiety on the N-terminal tyrosine blocks dipeptidyl aminopeptidase-4 (DPP-IV) cleavage, the enzymatic step that normally clips the Tyr¹-Ala² dipeptide from native GHRH and inactivates it within minutes. This is the engineering feature that makes subcutaneous dosing practical. Reported terminal half-life after SC injection in HIV patients on multiple dosing is 18.6–37.8 minutes, with Tmax ~8–10 minutes and linear dose-proportional PK across the 0.5–2 mg range (FDA Clinical Pharmacology Review; label for Egrifta / Egrifta WR, 2025).
In plain English
Why the chemical modification makes tesamorelin work as a drug
The body has an enzyme (DPP-IV) that normally destroys natural GHRH within minutes after it enters the bloodstream — it clips off the end of the molecule and inactivates it. That's why you can't just inject natural GHRH as a drug. Tesamorelin has a small chemical cap on that vulnerable end, blocking DPP-IV from cutting it. The result: tesamorelin lasts about 18–38 minutes after injection before being broken down. That's long enough to do its job. The drug gets to peak levels about 8–10 minutes after a subcutaneous (under-the-skin) injection, and the body handles it predictably across a range of doses.
- 03
Preservation of physiologic pulsatile GH secretion
A central mechanistic distinction of tesamorelin versus exogenous GH is that it drives endogenous somatotroph output while leaving the pulsatile architecture and IGF-1 negative-feedback loop intact. Stanley 2011 (JCEM) used 20-minute overnight GH sampling in a randomized crossover in healthy men and documented augmented basal and pulsatile GH with intact diurnal pattern; peripheral insulin-stimulated glucose uptake (measured by hyperinsulinemic-euglycemic clamp) was preserved. This is the physiology that rationalizes tesamorelin's more favorable glycemic profile compared with continuous GH replacement.
In plain English
Why it raises GH the natural way — not like an injection of GH itself
Your body releases GH in pulses throughout the day and night — not as a continuous drip. When you inject synthetic GH directly, you override that natural rhythm and flood the system at once. Tesamorelin works differently: it tells your pituitary to release more of its own GH in the normal pulsatile pattern. A 2011 study in healthy men sampled GH levels every 20 minutes overnight and confirmed that tesamorelin amplified those natural pulses without breaking the pattern. The same study showed blood-sugar handling stayed normal. That is the key advantage over injected GH: preserved rhythm, preserved insulin sensitivity.
- 04
IGF-1 rise and feedback-limited ceiling
GH released from somatotrophs drives hepatic IGF-1 production. In the pivotal Phase 3 program IGF-1 rose by approximately 181 ± 22 μg/L above baseline in tesamorelin-treated patients (Falutz 2007; FDA label). Critically, IGF-1 negative feedback on the hypothalamus and pituitary is not bypassed — mean IGF-1 remained within the normal physiologic range in the trials and serves as the monitoring biomarker required by the FDA label. This feedback-ceilinged design is what prevents the tonic IGF-1 excess seen with exogenous GH.
In plain English
How it raises IGF-1 with a built-in safety cap
Growth hormone tells your liver to make IGF-1 (insulin-like growth factor 1) — a hormone that helps cells grow and repair. When tesamorelin raises GH, IGF-1 goes up too — by about 181 units above baseline in the Phase 3 trials. Here's what matters: the body's own feedback system stays intact. When IGF-1 rises, the brain senses it and dials back GHRH and GH production — a natural governor. So IGF-1 stays inside the normal healthy range, not the dangerous elevated range you see with direct GH injections. The FDA requires monitoring IGF-1 during tesamorelin treatment to make sure it stays within bounds.
- 05
Depot-selective visceral lipolysis
The downstream phenotypic effect most relevant to the FDA indication is selective reduction of visceral (intra-abdominal) adipose tissue with preservation of subcutaneous fat and lean mass. Proposed drivers include differential GH-receptor density and hormone-sensitive-lipase responsiveness in visceral vs subcutaneous adipocytes and enhanced fatty-acid oxidation driven by GH-induced lipolysis. Falutz 2007 (NEJM) showed ~15.4% mean VAT reduction at 26 weeks on CT imaging with preservation of subcutaneous fat and a modest increase in lean body mass — a pharmacologic profile that is qualitatively different from non-selective weight-loss interventions.
In plain English
Why it targets deep belly fat specifically — not all fat
The fat packed around your organs (visceral fat — the dangerous kind) has more GH receptors than the fat under your skin. When GH rises, the internal fat responds more strongly — breaking down faster than subcutaneous fat. That's why tesamorelin shows preferential reduction of deep belly fat rather than all-over fat loss. The Phase 3 trials measured this precisely with CT scans and found about 15% less deep belly fat after 26 weeks on tesamorelin vs. placebo. Subcutaneous fat and muscle mass were preserved. This is a different profile from standard weight-loss drugs, which reduce all types of fat and often also reduce muscle.
- 06
Hepatic fat and NAFLD in HIV
Stanley 2019 (Lancet HIV) extended the lipolytic mechanism to liver: in 61 HIV patients with NAFLD randomized to tesamorelin or placebo for 12 months, the tesamorelin arm showed a -4.1 vs +0.9 percentage-point change in liver fat fraction on MR spectroscopy (p<0.001) and a numerical reduction in hepatic fibrosis progression. This positions tesamorelin as a GH-axis intervention with measurable hepatic-steatosis activity in the HIV population — a meaningful extension of mechanism beyond the approved VAT endpoint.
In plain English
Evidence that it also reduces fat in the liver (in HIV patients)
The same GH-driven fat-burning mechanism that targets belly fat also appears to work on fat stored in the liver. A 2019 trial published in The Lancet HIV enrolled 61 HIV patients who had fatty liver disease. After 12 months, the tesamorelin group's liver fat went down by 4.1 percentage points while the placebo group's went up by 0.9 points — a statistically meaningful difference measured by MRI. There was also a signal toward less liver scarring (fibrosis) in the tesamorelin group. This is outside the FDA-approved use (which covers belly fat, not liver fat), but it's the highest-quality evidence for this additional benefit.
- 07
What is NOT known about the mechanism
Whether the depot-selective visceral lipolysis and hepatic-fat effect documented in HIV-lipodystrophy and HIV-NAFLD populations generalizes to non-HIV adults with general-population obesity is unsettled — no Phase 3 exists in that population. The long-term oncologic implications of chronic feedback-ceilinged IGF-1 elevation across a broader population (given epidemiologic associations between serum IGF-1 and several malignancies) remain an open question that a ~26–52-week lipodystrophy trial is not powered to resolve. Tissue distribution of the albumin-unbound tesamorelin peptide and behavior under disease states (hepatic or renal impairment, hypoalbuminemia) are partially characterized in the FDA Clinical Pharmacology Review but remain thinner than the HIV-lipodystrophy efficacy data.
In plain English
What the science still can't answer
The belly-fat and liver-fat effects are proven in HIV patients with specific fat-distribution problems. Whether the same effects happen in healthy adults with ordinary obesity — without HIV or lipodystrophy — is genuinely unknown. No Phase 3 trial has tested this. The long-term cancer question is also open: IGF-1 at sustained elevated levels has been associated in population studies with higher rates of some cancers. A 26–52-week trial isn't big enough or long enough to detect that kind of risk. How the drug behaves in people with liver or kidney disease is only partially studied.